nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—ADRA1B—vas deferens—prostate cancer	0.127	0.777	CbGeAlD
Lisdexamfetamine—SLC18A2—prostate gland—prostate cancer	0.0112	0.0687	CbGeAlD
Lisdexamfetamine—ADRA1B—renal system—prostate cancer	0.00773	0.0473	CbGeAlD
Lisdexamfetamine—L-Lysine—SLC7A1—prostate cancer	0.00618	0.347	CrCbGaD
Lisdexamfetamine—SLC18A2—testis—prostate cancer	0.00495	0.0303	CbGeAlD
Lisdexamfetamine—SLC6A3—testis—prostate cancer	0.00374	0.0229	CbGeAlD
Lisdexamfetamine—SLC18A2—lymph node—prostate cancer	0.00359	0.0219	CbGeAlD
Lisdexamfetamine—SLC6A2—testis—prostate cancer	0.00302	0.0185	CbGeAlD
Lisdexamfetamine—Phenelzine—CYP3A43—prostate cancer	0.00236	0.133	CrCbGaD
Lisdexamfetamine—SLC6A2—lymph node—prostate cancer	0.00219	0.0134	CbGeAlD
Lisdexamfetamine—L-Phenylalanine—TH—prostate cancer	0.00151	0.085	CrCbGaD
Lisdexamfetamine—Lisinopril—ACE—prostate cancer	0.0011	0.062	CrCbGaD
Lisdexamfetamine—Amphetamine—SLC22A3—prostate cancer	0.000964	0.0542	CrCbGaD
Lisdexamfetamine—Methamphetamine—SLC22A3—prostate cancer	0.000894	0.0502	CrCbGaD
Lisdexamfetamine—Labetalol—ADRB2—prostate cancer	0.00073	0.041	CrCbGaD
Lisdexamfetamine—Selegiline—CYP2A6—prostate cancer	0.00065	0.0365	CrCbGaD
Lisdexamfetamine—Phenelzine—CYP3A5—prostate cancer	0.000592	0.0332	CrCbGaD
Lisdexamfetamine—Amphetamine—CYP2A6—prostate cancer	0.00054	0.0303	CrCbGaD
Lisdexamfetamine—Selegiline—CYP2E1—prostate cancer	0.000462	0.0259	CrCbGaD
Lisdexamfetamine—Selegiline—CYP2C19—prostate cancer	0.000457	0.0257	CrCbGaD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.00043	0.000671	CcSEcCtD
Lisdexamfetamine—Vomiting—Goserelin—prostate cancer	0.00043	0.00067	CcSEcCtD
Lisdexamfetamine—Constipation—Mitoxantrone—prostate cancer	0.000427	0.000666	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000426	0.000665	CcSEcCtD
Lisdexamfetamine—Rash—Goserelin—prostate cancer	0.000426	0.000665	CcSEcCtD
Lisdexamfetamine—Dermatitis—Goserelin—prostate cancer	0.000426	0.000664	CcSEcCtD
Lisdexamfetamine—Vomiting—Conjugated Estrogens—prostate cancer	0.000425	0.000664	CcSEcCtD
Lisdexamfetamine—Urticaria—Estradiol—prostate cancer	0.000425	0.000664	CcSEcCtD
Lisdexamfetamine—Mental disorder—Docetaxel—prostate cancer	0.000425	0.000664	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Capecitabine—prostate cancer	0.000425	0.000663	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Capecitabine—prostate cancer	0.000424	0.000661	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Estradiol—prostate cancer	0.000423	0.000661	CcSEcCtD
Lisdexamfetamine—Headache—Goserelin—prostate cancer	0.000423	0.00066	CcSEcCtD
Lisdexamfetamine—Malnutrition—Docetaxel—prostate cancer	0.000423	0.000659	CcSEcCtD
Lisdexamfetamine—Rash—Conjugated Estrogens—prostate cancer	0.000422	0.000658	CcSEcCtD
Lisdexamfetamine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000422	0.000658	CcSEcCtD
Lisdexamfetamine—Headache—Conjugated Estrogens—prostate cancer	0.000419	0.000654	CcSEcCtD
Lisdexamfetamine—Hallucination—Prednisone—prostate cancer	0.000417	0.00065	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Etoposide—prostate cancer	0.000415	0.000648	CcSEcCtD
Lisdexamfetamine—Mental disorder—Capecitabine—prostate cancer	0.000412	0.000643	CcSEcCtD
Lisdexamfetamine—Malnutrition—Capecitabine—prostate cancer	0.000409	0.000639	CcSEcCtD
Lisdexamfetamine—Phenelzine—CYP2E1—prostate cancer	0.000407	0.0228	CrCbGaD
Lisdexamfetamine—Tachycardia—Etoposide—prostate cancer	0.000405	0.000632	CcSEcCtD
Lisdexamfetamine—Skin disorder—Etoposide—prostate cancer	0.000403	0.000629	CcSEcCtD
Lisdexamfetamine—Phenelzine—CYP2C19—prostate cancer	0.000403	0.0226	CrCbGaD
Lisdexamfetamine—Nausea—Goserelin—prostate cancer	0.000401	0.000626	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Etoposide—prostate cancer	0.000401	0.000626	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Doxorubicin—prostate cancer	0.0004	0.000624	CcSEcCtD
Lisdexamfetamine—Nausea—Conjugated Estrogens—prostate cancer	0.000397	0.00062	CcSEcCtD
Lisdexamfetamine—Urticaria—Mitoxantrone—prostate cancer	0.000396	0.000619	CcSEcCtD
Lisdexamfetamine—Anorexia—Etoposide—prostate cancer	0.000396	0.000617	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Estradiol—prostate cancer	0.000395	0.000616	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Mitoxantrone—prostate cancer	0.000394	0.000616	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000394	0.000615	CcSEcCtD
Lisdexamfetamine—Eye disorder—Prednisone—prostate cancer	0.000391	0.000611	CcSEcCtD
Lisdexamfetamine—Vision blurred—Capecitabine—prostate cancer	0.000386	0.000602	CcSEcCtD
Lisdexamfetamine—Asthenia—Estradiol—prostate cancer	0.000384	0.0006	CcSEcCtD
Lisdexamfetamine—Tremor—Capecitabine—prostate cancer	0.000383	0.000598	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Prednisone—prostate cancer	0.000378	0.00059	CcSEcCtD
Lisdexamfetamine—Palpitations—Docetaxel—prostate cancer	0.000374	0.000583	CcSEcCtD
Lisdexamfetamine—Weight increased—Epirubicin—prostate cancer	0.000372	0.000581	CcSEcCtD
Lisdexamfetamine—Weight decreased—Epirubicin—prostate cancer	0.00037	0.000578	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Etoposide—prostate cancer	0.00037	0.000577	CcSEcCtD
Lisdexamfetamine—Somnolence—Etoposide—prostate cancer	0.000369	0.000576	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000368	0.000574	CcSEcCtD
Lisdexamfetamine—Mental disorder—Prednisone—prostate cancer	0.000367	0.000572	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Estradiol—prostate cancer	0.000366	0.000572	CcSEcCtD
Lisdexamfetamine—Convulsion—Docetaxel—prostate cancer	0.000366	0.000571	CcSEcCtD
Lisdexamfetamine—Hypertension—Docetaxel—prostate cancer	0.000365	0.000569	CcSEcCtD
Lisdexamfetamine—Malnutrition—Prednisone—prostate cancer	0.000364	0.000569	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000362	0.000564	CcSEcCtD
Lisdexamfetamine—Palpitations—Capecitabine—prostate cancer	0.000362	0.000564	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Etoposide—prostate cancer	0.000361	0.000563	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Etoposide—prostate cancer	0.000358	0.000559	CcSEcCtD
Lisdexamfetamine—Asthenia—Mitoxantrone—prostate cancer	0.000358	0.000559	CcSEcCtD
Lisdexamfetamine—Fatigue—Etoposide—prostate cancer	0.000358	0.000558	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000357	0.000558	CcSEcCtD
Lisdexamfetamine—Constipation—Etoposide—prostate cancer	0.000355	0.000554	CcSEcCtD
Lisdexamfetamine—Dizziness—Estradiol—prostate cancer	0.000354	0.000553	CcSEcCtD
Lisdexamfetamine—Hypertension—Capecitabine—prostate cancer	0.000353	0.000551	CcSEcCtD
Lisdexamfetamine—Dry mouth—Docetaxel—prostate cancer	0.000352	0.000549	CcSEcCtD
Lisdexamfetamine—Anxiety—Capecitabine—prostate cancer	0.000347	0.000542	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000346	0.00054	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Epirubicin—prostate cancer	0.000345	0.000538	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Docetaxel—prostate cancer	0.000345	0.000538	CcSEcCtD
Lisdexamfetamine—Weight increased—Doxorubicin—prostate cancer	0.000345	0.000538	CcSEcCtD
Lisdexamfetamine—Vision blurred—Prednisone—prostate cancer	0.000344	0.000536	CcSEcCtD
Lisdexamfetamine—Weight decreased—Doxorubicin—prostate cancer	0.000342	0.000534	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Mitoxantrone—prostate cancer	0.000341	0.000533	CcSEcCtD
Lisdexamfetamine—Dry mouth—Capecitabine—prostate cancer	0.000341	0.000532	CcSEcCtD
Lisdexamfetamine—Vomiting—Estradiol—prostate cancer	0.000341	0.000531	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Docetaxel—prostate cancer	0.000338	0.000528	CcSEcCtD
Lisdexamfetamine—Rash—Estradiol—prostate cancer	0.000338	0.000527	CcSEcCtD
Lisdexamfetamine—Dermatitis—Estradiol—prostate cancer	0.000337	0.000526	CcSEcCtD
Lisdexamfetamine—Tachycardia—Docetaxel—prostate cancer	0.000337	0.000525	CcSEcCtD
Lisdexamfetamine—Headache—Estradiol—prostate cancer	0.000335	0.000523	CcSEcCtD
Lisdexamfetamine—Skin disorder—Docetaxel—prostate cancer	0.000335	0.000523	CcSEcCtD
Lisdexamfetamine—Agitation—Prednisone—prostate cancer	0.000335	0.000523	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000335	0.000522	CcSEcCtD
Lisdexamfetamine—Angioedema—Prednisone—prostate cancer	0.000333	0.00052	CcSEcCtD
Lisdexamfetamine—Urticaria—Etoposide—prostate cancer	0.00033	0.000515	CcSEcCtD
Lisdexamfetamine—Anorexia—Docetaxel—prostate cancer	0.000329	0.000513	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Etoposide—prostate cancer	0.000328	0.000512	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Capecitabine—prostate cancer	0.000328	0.000511	CcSEcCtD
Lisdexamfetamine—Hepatitis—Epirubicin—prostate cancer	0.000327	0.000511	CcSEcCtD
Lisdexamfetamine—Tachycardia—Capecitabine—prostate cancer	0.000326	0.000509	CcSEcCtD
Lisdexamfetamine—Skin disorder—Capecitabine—prostate cancer	0.000324	0.000506	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Capecitabine—prostate cancer	0.000323	0.000504	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000319	0.000498	CcSEcCtD
Lisdexamfetamine—Anorexia—Capecitabine—prostate cancer	0.000318	0.000497	CcSEcCtD
Lisdexamfetamine—Nausea—Estradiol—prostate cancer	0.000318	0.000496	CcSEcCtD
Lisdexamfetamine—Vomiting—Mitoxantrone—prostate cancer	0.000317	0.000495	CcSEcCtD
Lisdexamfetamine—Convulsion—Prednisone—prostate cancer	0.000316	0.000493	CcSEcCtD
Lisdexamfetamine—Visual impairment—Epirubicin—prostate cancer	0.000316	0.000492	CcSEcCtD
Lisdexamfetamine—Hypertension—Prednisone—prostate cancer	0.000315	0.000491	CcSEcCtD
Lisdexamfetamine—Rash—Mitoxantrone—prostate cancer	0.000315	0.000491	CcSEcCtD
Lisdexamfetamine—Dermatitis—Mitoxantrone—prostate cancer	0.000314	0.00049	CcSEcCtD
Lisdexamfetamine—Headache—Mitoxantrone—prostate cancer	0.000313	0.000488	CcSEcCtD
Lisdexamfetamine—Insomnia—Docetaxel—prostate cancer	0.000312	0.000487	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Epirubicin—prostate cancer	0.00031	0.000483	CcSEcCtD
Lisdexamfetamine—Anxiety—Prednisone—prostate cancer	0.000309	0.000483	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000308	0.000481	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Docetaxel—prostate cancer	0.000308	0.00048	CcSEcCtD
Lisdexamfetamine—Somnolence—Docetaxel—prostate cancer	0.000307	0.000478	CcSEcCtD
Lisdexamfetamine—Eye disorder—Epirubicin—prostate cancer	0.000306	0.000478	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Etoposide—prostate cancer	0.000306	0.000477	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Epirubicin—prostate cancer	0.000304	0.000474	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Docetaxel—prostate cancer	0.000304	0.000474	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—prostate cancer	0.000303	0.000473	CcSEcCtD
Lisdexamfetamine—Insomnia—Capecitabine—prostate cancer	0.000302	0.000471	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Docetaxel—prostate cancer	0.0003	0.000468	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000298	0.000465	CcSEcCtD
Lisdexamfetamine—Asthenia—Etoposide—prostate cancer	0.000298	0.000465	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Capecitabine—prostate cancer	0.000298	0.000465	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Prednisone—prostate cancer	0.000297	0.000464	CcSEcCtD
Lisdexamfetamine—Fatigue—Docetaxel—prostate cancer	0.000297	0.000464	CcSEcCtD
Lisdexamfetamine—Nausea—Mitoxantrone—prostate cancer	0.000296	0.000462	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Epirubicin—prostate cancer	0.000296	0.000462	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Epirubicin—prostate cancer	0.000295	0.000461	CcSEcCtD
Lisdexamfetamine—Constipation—Docetaxel—prostate cancer	0.000295	0.00046	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Capecitabine—prostate cancer	0.000294	0.000459	CcSEcCtD
Lisdexamfetamine—Visual impairment—Doxorubicin—prostate cancer	0.000292	0.000456	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Prednisone—prostate cancer	0.000292	0.000455	CcSEcCtD
Lisdexamfetamine—Selegiline—CYP3A4—prostate cancer	0.000291	0.0163	CrCbGaD
Lisdexamfetamine—Tachycardia—Prednisone—prostate cancer	0.00029	0.000453	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Capecitabine—prostate cancer	0.00029	0.000453	CcSEcCtD
Lisdexamfetamine—Skin disorder—Prednisone—prostate cancer	0.000289	0.000451	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000288	0.00045	CcSEcCtD
Lisdexamfetamine—Fatigue—Capecitabine—prostate cancer	0.000288	0.000449	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Prednisone—prostate cancer	0.000288	0.000449	CcSEcCtD
Lisdexamfetamine—Mental disorder—Epirubicin—prostate cancer	0.000287	0.000448	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—prostate cancer	0.000286	0.000447	CcSEcCtD
Lisdexamfetamine—Constipation—Capecitabine—prostate cancer	0.000286	0.000446	CcSEcCtD
Lisdexamfetamine—Malnutrition—Epirubicin—prostate cancer	0.000285	0.000445	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Etoposide—prostate cancer	0.000284	0.000443	CcSEcCtD
Lisdexamfetamine—Anorexia—Prednisone—prostate cancer	0.000284	0.000442	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—prostate cancer	0.000283	0.000442	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—prostate cancer	0.000281	0.000439	CcSEcCtD
Lisdexamfetamine—Nervousness—Epirubicin—prostate cancer	0.000277	0.000432	CcSEcCtD
Lisdexamfetamine—Dizziness—Etoposide—prostate cancer	0.000274	0.000428	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—prostate cancer	0.000274	0.000427	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—prostate cancer	0.000273	0.000426	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Docetaxel—prostate cancer	0.000273	0.000425	CcSEcCtD
Lisdexamfetamine—Insomnia—Prednisone—prostate cancer	0.000269	0.00042	CcSEcCtD
Lisdexamfetamine—Vision blurred—Epirubicin—prostate cancer	0.000269	0.000419	CcSEcCtD
Lisdexamfetamine—Mental disorder—Doxorubicin—prostate cancer	0.000265	0.000414	CcSEcCtD
Lisdexamfetamine—Urticaria—Capecitabine—prostate cancer	0.000265	0.000414	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Capecitabine—prostate cancer	0.000264	0.000412	CcSEcCtD
Lisdexamfetamine—Vomiting—Etoposide—prostate cancer	0.000264	0.000412	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—prostate cancer	0.000264	0.000412	CcSEcCtD
Lisdexamfetamine—Agitation—Epirubicin—prostate cancer	0.000262	0.000409	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Prednisone—prostate cancer	0.000262	0.000409	CcSEcCtD
Lisdexamfetamine—Rash—Etoposide—prostate cancer	0.000262	0.000408	CcSEcCtD
Lisdexamfetamine—Dermatitis—Etoposide—prostate cancer	0.000261	0.000408	CcSEcCtD
Lisdexamfetamine—Headache—Etoposide—prostate cancer	0.00026	0.000406	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Prednisone—prostate cancer	0.000259	0.000404	CcSEcCtD
Lisdexamfetamine—Fatigue—Prednisone—prostate cancer	0.000256	0.0004	CcSEcCtD
Lisdexamfetamine—Nervousness—Doxorubicin—prostate cancer	0.000256	0.0004	CcSEcCtD
Lisdexamfetamine—Phenelzine—CYP3A4—prostate cancer	0.000256	0.0144	CrCbGaD
Lisdexamfetamine—Constipation—Prednisone—prostate cancer	0.000254	0.000397	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Docetaxel—prostate cancer	0.000254	0.000397	CcSEcCtD
Lisdexamfetamine—Palpitations—Epirubicin—prostate cancer	0.000252	0.000393	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—prostate cancer	0.000249	0.000388	CcSEcCtD
Lisdexamfetamine—Asthenia—Docetaxel—prostate cancer	0.000247	0.000386	CcSEcCtD
Lisdexamfetamine—Convulsion—Epirubicin—prostate cancer	0.000247	0.000385	CcSEcCtD
Lisdexamfetamine—Nausea—Etoposide—prostate cancer	0.000247	0.000385	CcSEcCtD
Lisdexamfetamine—Hypertension—Epirubicin—prostate cancer	0.000246	0.000384	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Capecitabine—prostate cancer	0.000246	0.000384	CcSEcCtD
Lisdexamfetamine—Agitation—Doxorubicin—prostate cancer	0.000242	0.000378	CcSEcCtD
Lisdexamfetamine—Anxiety—Epirubicin—prostate cancer	0.000242	0.000377	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000241	0.000376	CcSEcCtD
Lisdexamfetamine—Asthenia—Capecitabine—prostate cancer	0.00024	0.000374	CcSEcCtD
Lisdexamfetamine—Dry mouth—Epirubicin—prostate cancer	0.000237	0.00037	CcSEcCtD
Lisdexamfetamine—Urticaria—Prednisone—prostate cancer	0.000236	0.000369	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Docetaxel—prostate cancer	0.000236	0.000368	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Prednisone—prostate cancer	0.000235	0.000367	CcSEcCtD
Lisdexamfetamine—Palpitations—Doxorubicin—prostate cancer	0.000233	0.000364	CcSEcCtD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ITPR1—prostate cancer	0.000233	0.00131	CbGpPWpGaD
Lisdexamfetamine—Anaphylactic shock—Epirubicin—prostate cancer	0.000233	0.000363	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CB—prostate cancer	0.000229	0.00129	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—OR51E2—prostate cancer	0.000229	0.00129	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CX3CL1—prostate cancer	0.000229	0.00129	CbGpPWpGaD
Lisdexamfetamine—Convulsion—Doxorubicin—prostate cancer	0.000229	0.000357	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Capecitabine—prostate cancer	0.000229	0.000357	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Epirubicin—prostate cancer	0.000228	0.000356	CcSEcCtD
Lisdexamfetamine—Dizziness—Docetaxel—prostate cancer	0.000228	0.000356	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—prostate cancer	0.000228	0.000355	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000228	0.00128	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000228	0.00128	CbGpPWpGaD
Lisdexamfetamine—Tachycardia—Epirubicin—prostate cancer	0.000227	0.000354	CcSEcCtD
Lisdexamfetamine—SLC6A3—Neuronal System—PRKACB—prostate cancer	0.000227	0.00128	CbGpPWpGaD
Lisdexamfetamine—Skin disorder—Epirubicin—prostate cancer	0.000226	0.000353	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Epirubicin—prostate cancer	0.000225	0.000351	CcSEcCtD
Lisdexamfetamine—Anxiety—Doxorubicin—prostate cancer	0.000224	0.000349	CcSEcCtD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CASP3—prostate cancer	0.000224	0.00126	CbGpPWpGaD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000223	0.000348	CcSEcCtD
Lisdexamfetamine—Anorexia—Epirubicin—prostate cancer	0.000222	0.000346	CcSEcCtD
Lisdexamfetamine—Dizziness—Capecitabine—prostate cancer	0.000221	0.000345	CcSEcCtD
Lisdexamfetamine—Dry mouth—Doxorubicin—prostate cancer	0.00022	0.000343	CcSEcCtD
Lisdexamfetamine—Vomiting—Docetaxel—prostate cancer	0.000219	0.000342	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Prednisone—prostate cancer	0.000219	0.000342	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PRKCQ—prostate cancer	0.000218	0.00123	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PENK—prostate cancer	0.000218	0.00122	CbGpPWpGaD
Lisdexamfetamine—Rash—Docetaxel—prostate cancer	0.000217	0.000339	CcSEcCtD
Lisdexamfetamine—Dermatitis—Docetaxel—prostate cancer	0.000217	0.000339	CcSEcCtD
Lisdexamfetamine—Headache—Docetaxel—prostate cancer	0.000216	0.000337	CcSEcCtD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000216	0.00122	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—COMT—prostate cancer	0.000216	0.00121	CbGpPWpGaD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—prostate cancer	0.000215	0.000336	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RGS17—prostate cancer	0.000214	0.0012	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Prednisone—prostate cancer	0.000213	0.000333	CcSEcCtD
Lisdexamfetamine—Vomiting—Capecitabine—prostate cancer	0.000212	0.000331	CcSEcCtD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP9—prostate cancer	0.000211	0.00119	CbGpPWpGaD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—prostate cancer	0.000211	0.000329	CcSEcCtD
Lisdexamfetamine—Rash—Capecitabine—prostate cancer	0.000211	0.000329	CcSEcCtD
Lisdexamfetamine—Insomnia—Epirubicin—prostate cancer	0.00021	0.000328	CcSEcCtD
Lisdexamfetamine—Dermatitis—Capecitabine—prostate cancer	0.00021	0.000328	CcSEcCtD
Lisdexamfetamine—Tachycardia—Doxorubicin—prostate cancer	0.00021	0.000328	CcSEcCtD
Lisdexamfetamine—Headache—Capecitabine—prostate cancer	0.000209	0.000326	CcSEcCtD
Lisdexamfetamine—Skin disorder—Doxorubicin—prostate cancer	0.000209	0.000326	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000208	0.00117	CbGpPWpGaD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—prostate cancer	0.000208	0.000325	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Epirubicin—prostate cancer	0.000207	0.000324	CcSEcCtD
Lisdexamfetamine—Somnolence—Epirubicin—prostate cancer	0.000207	0.000323	CcSEcCtD
Lisdexamfetamine—Anorexia—Doxorubicin—prostate cancer	0.000205	0.00032	CcSEcCtD
Lisdexamfetamine—Nausea—Docetaxel—prostate cancer	0.000205	0.00032	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Epirubicin—prostate cancer	0.000205	0.00032	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000205	0.00115	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Prednisone—prostate cancer	0.000204	0.000318	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Epirubicin—prostate cancer	0.000202	0.000316	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000201	0.000313	CcSEcCtD
Lisdexamfetamine—Fatigue—Epirubicin—prostate cancer	0.000201	0.000313	CcSEcCtD
Lisdexamfetamine—Constipation—Epirubicin—prostate cancer	0.000199	0.00031	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—CDKN1A—prostate cancer	0.000198	0.00112	CbGpPWpGaD
Lisdexamfetamine—Nausea—Capecitabine—prostate cancer	0.000198	0.00031	CcSEcCtD
Lisdexamfetamine—Dizziness—Prednisone—prostate cancer	0.000197	0.000307	CcSEcCtD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCQ—prostate cancer	0.000195	0.0011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—SRC—prostate cancer	0.000195	0.0011	CbGpPWpGaD
Lisdexamfetamine—Insomnia—Doxorubicin—prostate cancer	0.000195	0.000304	CcSEcCtD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RGS17—prostate cancer	0.000195	0.00109	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—ITPR1—prostate cancer	0.000194	0.00109	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000194	0.00109	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.000193	0.00109	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000192	0.00108	CbGpPWpGaD
Lisdexamfetamine—Dyspnoea—Doxorubicin—prostate cancer	0.000192	0.000299	CcSEcCtD
Lisdexamfetamine—Somnolence—Doxorubicin—prostate cancer	0.000191	0.000299	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RLN2—prostate cancer	0.000191	0.00107	CbGpPWpGaD
Lisdexamfetamine—Dyspepsia—Doxorubicin—prostate cancer	0.000189	0.000296	CcSEcCtD
Lisdexamfetamine—Vomiting—Prednisone—prostate cancer	0.000189	0.000295	CcSEcCtD
Lisdexamfetamine—Rash—Prednisone—prostate cancer	0.000188	0.000293	CcSEcCtD
Lisdexamfetamine—Dermatitis—Prednisone—prostate cancer	0.000187	0.000292	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Doxorubicin—prostate cancer	0.000187	0.000292	CcSEcCtD
Lisdexamfetamine—Headache—Prednisone—prostate cancer	0.000186	0.000291	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000186	0.00029	CcSEcCtD
Lisdexamfetamine—Fatigue—Doxorubicin—prostate cancer	0.000186	0.00029	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GNRH1—prostate cancer	0.000185	0.00104	CbGpPWpGaD
Lisdexamfetamine—Urticaria—Epirubicin—prostate cancer	0.000185	0.000288	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000185	0.00104	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000184	0.00104	CbGpPWpGaD
Lisdexamfetamine—Constipation—Doxorubicin—prostate cancer	0.000184	0.000287	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Epirubicin—prostate cancer	0.000184	0.000287	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GRP—prostate cancer	0.000179	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—LPAR1—prostate cancer	0.000179	0.00101	CbGpPWpGaD
Lisdexamfetamine—Nausea—Prednisone—prostate cancer	0.000177	0.000276	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PLXNB1—prostate cancer	0.000175	0.000982	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CX3CL1—prostate cancer	0.000174	0.000979	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—prostate cancer	0.000174	0.000977	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RLN2—prostate cancer	0.000173	0.000975	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ANXA1—prostate cancer	0.000173	0.000974	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Epirubicin—prostate cancer	0.000171	0.000267	CcSEcCtD
Lisdexamfetamine—Urticaria—Doxorubicin—prostate cancer	0.000171	0.000267	CcSEcCtD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—EGFR—prostate cancer	0.000171	0.000961	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.00017	0.000958	CbGpPWpGaD
Lisdexamfetamine—Body temperature increased—Doxorubicin—prostate cancer	0.00017	0.000266	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.00017	0.000955	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRPR—prostate cancer	0.000168	0.000945	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Epirubicin—prostate cancer	0.000167	0.00026	CcSEcCtD
Lisdexamfetamine—SLC6A3—Neuronal System—COMT—prostate cancer	0.000165	0.000929	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.000163	0.000915	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—GNG5—prostate cancer	0.000162	0.000909	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GNG5—prostate cancer	0.000161	0.000906	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Epirubicin—prostate cancer	0.000159	0.000248	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—prostate cancer	0.000159	0.000892	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PLXNB1—prostate cancer	0.000159	0.000892	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—prostate cancer	0.000159	0.000247	CcSEcCtD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL12—prostate cancer	0.000158	0.000891	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—RXRA—prostate cancer	0.000155	0.00087	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Doxorubicin—prostate cancer	0.000154	0.000241	CcSEcCtD
Lisdexamfetamine—Dizziness—Epirubicin—prostate cancer	0.000154	0.00024	CcSEcCtD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRPR—prostate cancer	0.000153	0.000859	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000151	0.000846	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—MDM2—prostate cancer	0.000148	0.000834	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Epirubicin—prostate cancer	0.000148	0.000231	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Doxorubicin—prostate cancer	0.000147	0.00023	CcSEcCtD
Lisdexamfetamine—Rash—Epirubicin—prostate cancer	0.000147	0.000229	CcSEcCtD
Lisdexamfetamine—Dermatitis—Epirubicin—prostate cancer	0.000147	0.000229	CcSEcCtD
Lisdexamfetamine—Headache—Epirubicin—prostate cancer	0.000146	0.000227	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—GNG5—prostate cancer	0.000143	0.000805	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Doxorubicin—prostate cancer	0.000142	0.000222	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PTHLH—prostate cancer	0.00014	0.000789	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CA—prostate cancer	0.00014	0.000785	CbGpPWpGaD
Lisdexamfetamine—Nausea—Epirubicin—prostate cancer	0.000138	0.000216	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—MC2R—prostate cancer	0.000138	0.000776	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000138	0.000775	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Doxorubicin—prostate cancer	0.000137	0.000214	CcSEcCtD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—prostate cancer	0.000136	0.000765	CbGpPWpGaD
Lisdexamfetamine—Rash—Doxorubicin—prostate cancer	0.000136	0.000212	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—prostate cancer	0.000136	0.000212	CcSEcCtD
Lisdexamfetamine—ADRA1B—Signaling Pathways—OR51E2—prostate cancer	0.000135	0.00076	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—prostate cancer	0.000135	0.00076	CbGpPWpGaD
Lisdexamfetamine—Headache—Doxorubicin—prostate cancer	0.000135	0.00021	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ANXA1—prostate cancer	0.000132	0.000742	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—WNT4—prostate cancer	0.000131	0.000739	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—prostate cancer	0.000131	0.000735	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.00013	0.000731	CbGpPWpGaD
Lisdexamfetamine—Nausea—Doxorubicin—prostate cancer	0.000128	0.0002	CcSEcCtD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MC2R—prostate cancer	0.000125	0.000705	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000124	0.000697	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BMPR1B—prostate cancer	0.000124	0.000695	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CALCA—prostate cancer	0.000124	0.000695	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PENK—prostate cancer	0.000123	0.000692	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000122	0.000686	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—prostate cancer	0.000121	0.000681	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL12—prostate cancer	0.000121	0.000679	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—PPARA—prostate cancer	0.000118	0.000665	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB1—prostate cancer	0.000117	0.000657	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000115	0.000649	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.000115	0.000647	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RGS17—prostate cancer	0.000115	0.000646	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—prostate cancer	0.000114	0.000641	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PENK—prostate cancer	0.000112	0.000628	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.00011	0.000617	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.000109	0.000616	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—prostate cancer	0.000107	0.000599	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—VIP—prostate cancer	0.000105	0.000588	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNRH1—prostate cancer	0.000105	0.000588	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—RXRA—prostate cancer	0.000104	0.000586	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRB2—prostate cancer	0.000104	0.000582	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB1—prostate cancer	0.000103	0.000582	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RLN2—prostate cancer	0.000102	0.000576	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—LPAR1—prostate cancer	0.000101	0.00057	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GRP—prostate cancer	0.000101	0.00057	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PLCB2—prostate cancer	0.0001	0.000564	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HSD17B1—prostate cancer	9.77e-05	0.00055	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CTBP2—prostate cancer	9.77e-05	0.00055	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—prostate cancer	9.72e-05	0.000546	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—NCOA1—prostate cancer	9.7e-05	0.000545	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PDE4D—prostate cancer	9.57e-05	0.000538	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—VIP—prostate cancer	9.5e-05	0.000534	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNRH1—prostate cancer	9.5e-05	0.000534	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	9.39e-05	0.000528	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLXNB1—prostate cancer	9.37e-05	0.000527	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—RXRA—prostate cancer	9.23e-05	0.000519	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—LPAR1—prostate cancer	9.2e-05	0.000518	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GRP—prostate cancer	9.2e-05	0.000518	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PLCB2—prostate cancer	9.11e-05	0.000512	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNG5—prostate cancer	9.1e-05	0.000512	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRPR—prostate cancer	9.02e-05	0.000507	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CX3CL1—prostate cancer	8.93e-05	0.000502	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—MDM2—prostate cancer	8.84e-05	0.000497	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL17RD—prostate cancer	8.71e-05	0.00049	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PDE4D—prostate cancer	8.69e-05	0.000489	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNG5—prostate cancer	8.27e-05	0.000465	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PPARA—prostate cancer	7.96e-05	0.000447	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PTHLH—prostate cancer	7.93e-05	0.000446	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JUP—prostate cancer	7.76e-05	0.000437	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—WNT4—prostate cancer	7.76e-05	0.000437	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ANXA1—prostate cancer	7.46e-05	0.000419	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RALBP1—prostate cancer	7.41e-05	0.000417	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MC2R—prostate cancer	7.41e-05	0.000417	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTHLH—prostate cancer	7.2e-05	0.000405	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKACB—prostate cancer	7.05e-05	0.000396	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PPARA—prostate cancer	7.05e-05	0.000396	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CALCA—prostate cancer	6.98e-05	0.000393	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PPP3CA—prostate cancer	6.87e-05	0.000386	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL12—prostate cancer	6.82e-05	0.000383	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ANXA1—prostate cancer	6.77e-05	0.000381	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PENK—prostate cancer	6.6e-05	0.000371	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	6.57e-05	0.000369	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	6.48e-05	0.000364	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CALCA—prostate cancer	6.34e-05	0.000357	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	6.32e-05	0.000355	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GHR—prostate cancer	6.3e-05	0.000354	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—prostate cancer	6.29e-05	0.000354	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PRKCQ—prostate cancer	6.22e-05	0.00035	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL12—prostate cancer	6.19e-05	0.000348	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	6.12e-05	0.000344	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NRP1—prostate cancer	6.04e-05	0.00034	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRB2—prostate cancer	5.85e-05	0.000329	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—VAV3—prostate cancer	5.71e-05	0.000321	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKCQ—prostate cancer	5.65e-05	0.000318	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	5.63e-05	0.000316	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNRH1—prostate cancer	5.61e-05	0.000316	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VIP—prostate cancer	5.61e-05	0.000316	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—CREBBP—prostate cancer	5.6e-05	0.000315	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ITPR1—prostate cancer	5.53e-05	0.000311	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LPAR1—prostate cancer	5.44e-05	0.000306	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRP—prostate cancer	5.44e-05	0.000306	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLCB2—prostate cancer	5.38e-05	0.000303	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LRP2—prostate cancer	5.38e-05	0.000303	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRB2—prostate cancer	5.31e-05	0.000299	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CX3CL1—prostate cancer	5.28e-05	0.000297	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—P4HB—prostate cancer	5.28e-05	0.000297	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—VAV3—prostate cancer	5.18e-05	0.000291	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIST1H2BG—prostate cancer	5.18e-05	0.000291	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRB7—prostate cancer	5.13e-05	0.000289	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDE4D—prostate cancer	5.13e-05	0.000289	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ITPR1—prostate cancer	5.03e-05	0.000283	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIST1H4H—prostate cancer	5e-05	0.000281	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL8—prostate cancer	5e-05	0.000281	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	4.98e-05	0.00028	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNG5—prostate cancer	4.88e-05	0.000275	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFBR1—prostate cancer	4.25e-05	0.000239	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTHLH—prostate cancer	4.25e-05	0.000239	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKR1C3—prostate cancer	4.19e-05	0.000235	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKACB—prostate cancer	4.16e-05	0.000234	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPP3CA—prostate cancer	4.06e-05	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—THBS1—prostate cancer	4.06e-05	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ANXA1—prostate cancer	4e-05	0.000225	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCZ—prostate cancer	3.93e-05	0.000221	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CG—prostate cancer	3.84e-05	0.000216	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PARP1—prostate cancer	3.79e-05	0.000213	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGFR4—prostate cancer	3.79e-05	0.000213	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CALCA—prostate cancer	3.75e-05	0.000211	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL12—prostate cancer	3.66e-05	0.000206	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CG—prostate cancer	3.49e-05	0.000196	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP9—prostate cancer	3.45e-05	0.000194	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CD—prostate cancer	3.37e-05	0.00019	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NGFR—prostate cancer	3.34e-05	0.000188	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCQ—prostate cancer	3.34e-05	0.000188	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAP3K7—prostate cancer	3.3e-05	0.000185	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF10—prostate cancer	3.17e-05	0.000178	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRB2—prostate cancer	3.14e-05	0.000176	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—JAK2—prostate cancer	3.1e-05	0.000174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAP2K1—prostate cancer	3.08e-05	0.000173	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CD—prostate cancer	3.06e-05	0.000172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VAV3—prostate cancer	3.06e-05	0.000172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFBR2—prostate cancer	3.02e-05	0.00017	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ITPR1—prostate cancer	2.97e-05	0.000167	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CB—prostate cancer	2.94e-05	0.000165	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1R—prostate cancer	2.84e-05	0.00016	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL8—prostate cancer	2.83e-05	0.000159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—JAK2—prostate cancer	2.81e-05	0.000158	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LPL—prostate cancer	2.72e-05	0.000153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL2—prostate cancer	2.7e-05	0.000152	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDGFRB—prostate cancer	2.7e-05	0.000152	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CB—prostate cancer	2.67e-05	0.00015	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ITGB3—prostate cancer	2.63e-05	0.000148	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL8—prostate cancer	2.57e-05	0.000144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB3—prostate cancer	2.55e-05	0.000143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGFR2—prostate cancer	2.55e-05	0.000143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL2—prostate cancer	2.45e-05	0.000138	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TERT—prostate cancer	2.44e-05	0.000137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIF1A—prostate cancer	2.34e-05	0.000131	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LEP—prostate cancer	2.28e-05	0.000128	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CAV1—prostate cancer	2.26e-05	0.000127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KDR—prostate cancer	2.23e-05	0.000126	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ESR1—prostate cancer	2.18e-05	0.000122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BAD—prostate cancer	2.13e-05	0.00012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APC—prostate cancer	2.06e-05	0.000116	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CG—prostate cancer	2.06e-05	0.000116	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGF—prostate cancer	2.04e-05	0.000114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IRS1—prostate cancer	2.04e-05	0.000114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GSK3B—prostate cancer	1.98e-05	0.000111	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—INS—prostate cancer	1.95e-05	0.00011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CREBBP—prostate cancer	1.91e-05	0.000107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1—prostate cancer	1.89e-05	0.000106	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EGFR—prostate cancer	1.88e-05	0.000105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAP2K1—prostate cancer	1.82e-05	0.000102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CD—prostate cancer	1.81e-05	0.000102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—prostate cancer	1.79e-05	0.000101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SERPINE1—prostate cancer	1.79e-05	0.000101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—prostate cancer	1.77e-05	9.96e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF2—prostate cancer	1.73e-05	9.74e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOS3—prostate cancer	1.71e-05	9.61e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JAK2—prostate cancer	1.66e-05	9.34e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—prostate cancer	1.63e-05	9.15e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MDM2—prostate cancer	1.62e-05	9.12e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	1.6e-05	8.99e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	1.58e-05	8.87e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	1.52e-05	8.52e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	1.48e-05	8.32e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	1.46e-05	8.23e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—prostate cancer	1.45e-05	8.16e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL2—prostate cancer	1.45e-05	8.15e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—prostate cancer	1.44e-05	8.11e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCND1—prostate cancer	1.41e-05	7.94e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	1.4e-05	7.86e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—prostate cancer	1.37e-05	7.71e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	1.37e-05	7.68e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTEN—prostate cancer	1.36e-05	7.66e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	1.33e-05	7.48e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EP300—prostate cancer	1.3e-05	7.31e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SRC—prostate cancer	1.26e-05	7.11e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	1.23e-05	6.92e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—prostate cancer	1.22e-05	6.86e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—prostate cancer	1.13e-05	6.37e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	1.13e-05	6.35e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGFR—prostate cancer	1.11e-05	6.23e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—prostate cancer	1.05e-05	5.89e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	9.62e-06	5.41e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—prostate cancer	9.3e-06	5.23e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—prostate cancer	8.52e-06	4.79e-05	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—prostate cancer	7.86e-06	4.42e-05	CbGpPWpGaD
